What is the ROE (Return on Equity) of Globeimmune this year?
The ROE of Globeimmune this year is 0 undefined.
Globeimmune ROE 2024
Globeimmune ROE
0
Ticker
GBIM
ISIN
US37957B1008
WKN
A1J41J
In 2024, Globeimmune's return on equity (ROE) was 0, a 0% increase from the 0 ROE in the previous year.
Globeimmune Aktienanalyse
What does Globeimmune do?
Globeimmune Inc. is a biopharmaceutical company that focuses on the development of immunotherapies for various types of cancer. The company was founded in 1998 in Louisville, Colorado, USA, and went public in 2014. Globeimmune's business model revolves around the use of its patented Tarmogen technology, which aims to activate the immune system against cancer cells. The company has conducted clinical studies for its treatments targeting pancreatic, lung, and prostate cancer. Globeimmune has also formed partnerships with other pharmaceutical companies, including one with Sanko Junyaku in Japan to market its Tarmogen technology in Asia. The company's product range includes various immunotherapies based on the Tarmogen technology, such as GI-4000 for pancreatic cancer, GI-6207 for prostate cancer, and GI-6301 for lung cancer. Globeimmune has achieved success in recent years, including completing a financing round of $15.6 million in 2012 and going public with a $35 million IPO in 2014. Overall, Globeimmune is a promising biopharmaceutical company that focuses on developing effective immunotherapies for cancer patients using its Tarmogen technology, which has the potential to revolutionize cancer treatment and provide patients with effective and gentle therapies. Globeimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Globeimmune's Return on Equity (ROE)
Globeimmune's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Globeimmune's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Globeimmune's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Globeimmune’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Globeimmune stock
How has the Return on Equity (ROE) of Globeimmune developed compared to the previous year?
The ROE of Globeimmune has increased by 0% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Globeimmune?
A high ROE indicates that Globeimmune generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Globeimmune?
A low ROE can indicate that Globeimmune is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Globeimmune affect the company?
A change in ROE (Return on Equity) of Globeimmune can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Globeimmune?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Globeimmune?
Some factors that can influence Globeimmune's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Globeimmune pay?
Over the past 12 months, Globeimmune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Globeimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Globeimmune?
The current dividend yield of Globeimmune is .
When does Globeimmune pay dividends?
Globeimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Globeimmune?
Globeimmune paid dividends every year for the past 0 years.
What is the dividend of Globeimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Globeimmune located?
Globeimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Globeimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Globeimmune from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.
When did Globeimmune pay the last dividend?
The last dividend was paid out on 9/21/2024.
What was the dividend of Globeimmune in the year 2023?
In the year 2023, Globeimmune distributed 0 USD as dividends.
In which currency does Globeimmune pay out the dividend?
The dividends of Globeimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Globeimmune
Our stock analysis for Globeimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Globeimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
